

AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings of the claims in the application.

1. **(Currently amended)** A method of treating pulmonary infection in a patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is from once a day to [[every]] once a week during a 14-day treatment period, or (iii) both; [[and]] wherein the liposomal/complexed antiinfective comprises at least one sterol; wherein the antiinfective is an aminoglycoside, and wherein the liposomal/complexed antiinfective has a lipid to drug ratio of less than 2.5:1.

2-4. **(Canceled).**

5. **(Currently amended)** The method of treating of claim 1[[4]], wherein the administrated amount is 100 mg or less for every day of treatment.

6. **(Previously presented)** The method of treating of claim 5, wherein the dosing is once a day.

7. **(Previously presented)** The method of treating of claim 5, wherein the dosing is once every two days.

8. **(Previously presented)** The method of treating of claim 5, wherein the dosing is once every three days.

9. **(Previously presented)** The method of treating of claim 1, wherein the antiinfective is amikacin.

10. **(Previously presented)** The method of treating of claim 9, wherein the administrated amount is 100 mg or less for every day of treatment.

11. **(Previously presented)** The method of treating of claim 10, wherein the dosing is once a day.

12. **(Previously presented)** The method of treating of claim 10, wherein the dosing is once every two days.

13. **(Previously presented)** The method of treating of claim 10, wherein the dosing is once every three days.

14. **(Previously presented)** The method of treating of claim 1, wherein the infection to be treated is a *Pseudomonas*, staphylococcal, streptococcal, *Escherichia coli*, *Klebsiella*, *Enterobacter*, *Serratia*, *Haemophilus*, *Yersinia pestis*, *Burkholderia*, *Mycobacterium*, *M. fortuitum complex*, or *M. avium complex* infection.

15. **(Previously presented)** The method of treating of claim 1, wherein the infection to be treated is a pseudomonas infection.

16. **(Previously presented)** The method of treating of claim 1, wherein the infection to be treated or ameliorated is a *P. aeruginosa* infection.

17. **(Previously presented)** The method of treating of claim 1, wherein the administrated amount is 50% or less of the comparative free drug amount

18. **(Previously presented)** The method of treating of claim 17, wherein the dosing is once a day.

19. **(Previously presented)** The method of treating of claim 17, wherein the dosing is once every two days.

20. **(Previously presented)** The method of treating of claim 17, wherein the dosing is once every three days.

21. **(Previously presented)** The method of treating of claim 1, wherein the administrated amount is 35% or less of the comparative free drug amount.

22. **(Previously presented)** The method of treating of claim 1, wherein the administrated amount is 20% or less of the comparative free drug amount.

23. **(Previously presented)** The method of treating of claim 1, wherein the administrated amount is 10% or less of the comparative free drug amount.

24. **(Previously presented)** The method of treating of claim 1, wherein the effective amount is one effective to treat after symptoms of lung infection have arisen

25. **(Currently amended)** A method of treating pulmonary infection in an animal comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative

free drug amount, and (ii) the dosing is once every two days during a 14 day treatment period; [[and]] wherein the liposomal/complexed antiinfective comprises at least one sterol; wherein the antiinfective is an aminoglycoside, and wherein the liposomal/complexed antiinfective has a lipid to drug ratio of less than 2.5:1.

26. **(Previously presented)** The method of claim 14, wherein the infection is selected from the group consisting of *P. aeruginosa*, *P. paucimobilis*, *P. putida*, *P. fluorescens*, *P. acidovorans*, Methicillin-resistant *Staphylococcus aureus* (MRSA), *Streptococcus pneumoniae*, *B. pseudomallei*, *B. cepacia*, *B. gladioli*, *B. multivorans*, *B. vietnamiensis*, *M. tuberculosis*, *M. avium* and *M. intracellulare*, *M. kansasii*, *M. xenopi*, *M. marinum*, *M. ulcerans*, *M. fortuitum* and *M. chelonei*.

27. **(Currently amended)** The method of claim 1, wherein the dosing is once a day, once every other day, once every third day, or once a [[every]] week.

28. **(Previously presented)** The method of claim 1, wherein the sterol is cholesterol.

29. **(Previously presented)** The method of claim 1, wherein the patient is a cystic fibrosis patient.

30. **(Previously presented)** The method of claim 1, wherein the infection is tuberculosis.